[{"id":"84e4e85b-e9f7-4b35-bc39-067c74a8a32d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05337735","created_at":"2022-04-20T15:53:51.350Z","updated_at":"2024-07-02T16:34:58.974Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers","source_id_and_acronym":"NCT05337735","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Suspended","enrollment":" Enrollment 140","initiation":"Initiation: 08/05/2022","start_date":" 08/05/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-06-04"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"8b035599-60c6-4e12-a848-25b7b29e695c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005728","created_at":"2021-08-13T12:53:42.693Z","updated_at":"2024-07-02T16:35:16.340Z","phase":"Phase 2","brief_title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05005728","lead_sponsor":"Xencor, Inc.","biomarkers":" TMB • MSI • HRD","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • docetaxel • cabazitaxel • vudalimab (XmAb717)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-05"},{"id":"fa288c29-592d-4dfb-ba55-267713dd3131","acronym":"DUET-2","url":"https://clinicaltrials.gov/study/NCT03517488","created_at":"2021-01-18T17:18:50.722Z","updated_at":"2024-07-02T16:35:59.763Z","phase":"Phase 1","brief_title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT03517488 - DUET-2","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2022-12-01"},{"id":"0dff7f04-3f58-49c6-8eb8-ea8e8e1ba046","acronym":"","url":"https://clinicaltrials.gov/study/NCT05453799","created_at":"2022-07-12T10:54:40.764Z","updated_at":"2024-07-02T16:36:04.939Z","phase":"Phase 2","brief_title":"Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer","source_id_and_acronym":"NCT05453799","lead_sponsor":"Northwestern University","biomarkers":" BRAF • CD4","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2022-08-24"}]